Skip to main content
. 2023 Jun 5;130(12):2061–2075. doi: 10.1017/S0007114523001253

Table 1.

Participant characteristics at baseline*

Control group (n 36) LFD group (n 34)
n % n %
Female/male 29/7 81/19 30/4 88/12
Age (years)
  Mean 45 46
  sd 15 13
European 36 100 34 100
BMI (kg/m2)
  Median 25† 25
  25th, 75th percentile 23, 28 22, 27
BMI category
  Underweight (< 18·5) 0† 0 1 3
  Normal weight (18·5–24·9) 17† 49 16 47
  Overweight (25·0–29·9) 13† 37 13 38
  Obese (> 30·0) 5† 14 4 12
Education level
  Primary school 1 3 1 3
  High school 13 36 5 15
  University/college, lower degree 12 33 14 41
  University/college, higher degree 10 28 14 41
Allergy/intolerance 14 39 17 50
CeD diagnostics
  Duration of CeD (years)
   Median 7 9
   25th, 75th percentile 4, 15 5, 14
  Anti-tTG2 IgA (103 U/L)
   Median 0·5 0·5
   25th, 75th percentile 0·5, 1·4 0·5, 1·5
  Anti-DGP IgG (U)
   Median 2·5 2·5
   25th, 75th percentile 2·5, 4·4 2·5, 2·5
  HLA DQ 2 27‡ 82 28§ 88§
  HLA DQ 8 6‡ 18 13§
  Marsh score 0 26 72 25 74
  Marsh score 1 10 28 9 27
GSRS-IBS total score||
  Mean 37 39
  sd 13 11
*

Values are presented as n and percentage for categorical variables, means with sd for normally distributed variables or medians with 25th and 75th percentile for non-normally distributed variables. Median is used for variables where data were not normally distributed in at least one group. LFD, low FODMAP diet; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides and polyols; CeD, coeliac disease; tTG, tissue transglutaminase; DGP, deaminated gliadin peptide; HLA, human leukocyte antigen; GSRS-IBS, gastrointestinal symptom rating scale IBS version; IBS, irritable bowel syndrome.

n 35 (one missing).

n 33 (three missing).

§

n 32 (two missing).

||

GSRS-IBS total scores are presented as mean with sd but are not checked for normality because the method is based on the mean independently of normality.